Tigermed
Tigermed
Tigermed is a contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.
Tigermed, founded in December, 2014 and headquartered in Hangzhou, is a contract research organization (CRO) focused on providing professional services for the entire process of clinical trials for new drug research. The founder is Ye Xiaoping. Listed on the SZSE on August 17, 2012, the company's major shareholders are Ye Xiaoping, Hong Kong Securities Clearing Co., Ltd and Cao Xiaochun. Rivals that have direct and indirect competition with Tigermed include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
- All
- News
- Analysis
- Research
Briefing Yesterday 11:57 AM
· Healthcare
Triarm therapeutics completed a round of financing of US $60 million
In depth
Briefing Sep 03, 2021 05:42 PM
· Healthcare
Nuocheng Jianhua and kangnoah deepen strategic cooperation and develop first in class macromolecular innovative drugs
Research
Technology, Consumer Staples, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Industrials, Financials, AutomotiveTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Industrials, Financials, AutomotiveLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Insight
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Briefing Jul 12, 2021 10:20 AM
Cro concept stocks rebounded across the board, and Boteng shares rose 14%
Briefing Jul 06, 2021 10:59 AM
· Healthcare
Blu ray development responds that Huaxia Bank and Vanke will take shares: unconfirmed market rumors
In depth
Healthcare
WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell
According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index. It has been considered a top holding by many MSCI China indexes for some time.
Jun 08, 2020 09:51 AM
Briefing Jan 27, 2021 06:29 PM
· Healthcare
Tiger pharmaceutical performance forecast: net profit in 2020 will increase by 100% - 115% year on year
Briefing Sep 03, 2020 01:27 PM
· Healthcare
Tigermed Invests in Tongli Biomedical to Treat Parasitic Zoonoses
Briefing Aug 31, 2020 12:46 PM
· Healthcare
Chinese Biopharma Adlai Nortye Closes Series C at USD 100 Mn
Briefing Aug 07, 2020 07:51 PM
· Healthcare
TigerMed: New to be the Third Dual-listed CRO on HKEX and A-share
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- More Room for the Medical Device Market to Grow in China
- Modern Chinese Medicine Maker Tasly Pharmaceutical: An Old Stock in a New Package?
- Haier Balances Smart Home Demand at Home and Overseas Trends
- TuSimple: Start with the Low-Hanging Fruit
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.